- Home
- MNDO vs ICCC Comparison
MNDO vs ICCC Comparison
Compare MNDO & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDO
- ICCC
- Stock Information
- Founded
- MNDO 1995
- ICCC 1982
- Country
- MNDO Israel
- ICCC United States
- Employees
- MNDO N/A
- ICCC N/A
- Industry
- MNDO EDP Services
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- MNDO Technology
- ICCC Health Care
- Exchange
- MNDO Nasdaq
- ICCC Nasdaq
- Market Cap
- MNDO 39.9M
- ICCC 39.2M
- IPO Year
- MNDO 2000
- ICCC 1987
- Fundamental
- Price
- MNDO $2.10
- ICCC $5.02
- Analyst Decision
- MNDO
- ICCC
- Analyst Count
- MNDO 0
- ICCC 0
- Target Price
- MNDO N/A
- ICCC N/A
- AVG Volume (30 Days)
- MNDO 46.8K
- ICCC 4.1K
- Earning Date
- MNDO 03-05-2025
- ICCC 02-25-2025
- Dividend Yield
- MNDO 11.43%
- ICCC N/A
- EPS Growth
- MNDO N/A
- ICCC N/A
- EPS
- MNDO 0.23
- ICCC N/A
- Revenue
- MNDO $21,856,000.00
- ICCC $23,838,001.00
- Revenue This Year
- MNDO N/A
- ICCC N/A
- Revenue Next Year
- MNDO N/A
- ICCC N/A
- P/E Ratio
- MNDO $9.13
- ICCC N/A
- Revenue Growth
- MNDO 2.27
- ICCC 46.37
- 52 Week Low
- MNDO $1.70
- ICCC $3.34
- 52 Week High
- MNDO $2.28
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- MNDO 56.56
- ICCC 47.31
- Support Level
- MNDO $2.07
- ICCC $4.84
- Resistance Level
- MNDO $2.13
- ICCC $5.25
- Average True Range (ATR)
- MNDO 0.05
- ICCC 0.27
- MACD
- MNDO 0.00
- ICCC -0.04
- Stochastic Oscillator
- MNDO 78.57
- ICCC 27.27
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets and implements real-time and off-line convergent billing and customer care software solutions. The company derives revenue from sale of software products and services in two operating segments namely Billing and Related Services, which derives key revenue and Messaging. The Company has three product lines: Product line A- billing and customer care solutions for service providers; Product line B - call accounting and call management solutions for enterprises; and Product line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in The Americas, Europe, Asia Pacific and Africa and Israel. It earns maximum revenue from Europe.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.